Nasdaq:BIIB
BIOGEN INC.
A premier biotech innovator focused on life-changing treatments for complex neurological diseases with a strong balance sheet and diverse product portfolio.
Key Metrics
Investment Thesis
Bull Case
Biogen offers a compelling value opportunity as its pipeline matures with new assets moving into late-stage development, potentially replacing revenue lost to patent expirations on legacy products. The company's diversified geographic footprint and strong operating cash flow of over $2 billion provide financial resilience to navigate the competitive landscape and fund transformative R&D initiatives.
Bear Case
Investors may hesitate due to the persistent decline in top-line revenue from 2022 levels, suggesting a shrinking addressable market or failing new drug approvals. High interest expenses of $267.5M and accumulated other comprehensive losses indicate sensitivity to macroeconomic conditions and potential regulatory setbacks that could further compress already thin margins.
About BIOGEN INC.
Biogen Inc. is a leading global biotechnology company specializing in developing and commercializing innovative therapies for serious neurological and neurodegenerative disorders, primarily serving patients with Alzheimer's disease, ALS, and other rare conditions across North America, Europe, and Asia.
Analysis
Management Discussion
The company reported revenue of $9.89B in 2025, reflecting a slight recovery after a multi-year decline from its 2022 peak of $10.17B, while net income stabilized at $1.29B following a sharp drop in 2023 but remaining below the 2024 high of $1.63B. Cash flow from operations remains robust at $2.20B, providing ample liquidity to fund R&D and strategic investments despite capital expenditures of $153.8M and significant debt activity involving $1.73B in issuances offset by $1.75B in repayments.
Industry Overview
The global neurodegenerative disease sector is experiencing rapid growth driven by an aging population and advancements in targeted therapies, yet it remains highly competitive with stringent FDA approval processes and high R&D failure rates. Companies like Biogen must continuously innovate to capture market share against established players developing similar mechanisms of action for Alzheimer's and ALS.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $10.17B | $9.84B | $9.68B | $9.89B |
| Cost of Revenue | $2.28B | $2.53B | $2.31B | $2.40B |
| Gross Profit | $7.90B | $7.30B | $7.37B | $7.49B |
| Operating Expenses | $4.30B | $6.01B | $5.46B | $5.93B |
| Operating Income | $3.59B | $1.30B | $1.91B | $1.56B |
| G&A | $2.40B | $2.55B | $2.40B | $2.43B |
| Stock-Based Comp | $254.1M | $264.2M | $291.2M | $290.8M |
| D&A | $518.4M | $494.8M | $673.2M | $779.9M |
| Depreciation | $272.4M | $254.2M | $286.7M | $272.8M |
| Amortization | $246.3M | $240.6M | $386.5M | $507.1M |
| Other OpEx | $1.90B | $3.46B | $3.06B | $3.50B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $246.6M | $246.9M | $250.3M | $267.5M |
| Interest Income | $89.3M | $276.5M | $67.6M | $125.0M |
| Pre-Tax Income | $3.59B | $1.30B | $1.91B | $1.56B |
| Income Tax | $632.8M | $135.3M | $273.8M | $263.6M |
| Continuing Ops | $2.96B | $1.16B | $1.63B | $1.29B |
| Discontinued Ops | $2.6M | $0 | $0 | $0 |
| Net Income | $2.96B | $1.16B | $1.63B | $1.29B |
| Minority Interest | $-85.3M | $400.0K | $0 | $0 |
| Net to Common | $3.05B | $1.16B | $1.63B | $1.29B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $9.79B | $6.86B | $7.46B | $8.97B |
| Accounts Receivable | $1.71B | $1.66B | $1.40B | $1.34B |
| Inventory | $1.34B | $2.53B | $2.46B | $2.17B |
| Other Current Assets | $6.74B | $2.67B | $3.59B | $5.46B |
| Long-Term Assets | $14.76B | $19.99B | $20.59B | $20.47B |
| PP&E (Net) | $3.30B | $3.31B | $3.18B | $3.06B |
| Intangibles | $1.85B | $8.36B | $9.69B | $9.18B |
| Goodwill | $5.75B | $6.22B | $6.48B | $6.49B |
| Operating Leases | $403.9M | $420.0M | $356.4M | $265.4M |
| Other LT Assets | $3.46B | $1.67B | $884.7M | $1.48B |
| Total Assets | $24.55B | $26.84B | $28.05B | $29.44B |
| Current Liabilities | $3.27B | $3.43B | $5.53B | $3.35B |
| Accounts Payable | $491.5M | $403.3M | $424.2M | $432.0M |
| Current Leases | $97.2M | $90.3M | $86.4M | $80.4M |
| Other Current Liab | $2.68B | $2.94B | $5.02B | $2.84B |
| Long-Term Liabilities | $7.89B | $8.61B | $5.80B | $7.83B |
| LT Operating Leases | $333.0M | $400.0M | $334.5M | $290.4M |
| Other LT Liab | $7.02B | $7.81B | $5.31B | $7.38B |
| Total Liabilities | $11.17B | $12.05B | $11.33B | $11.18B |
| Shareholders' Equity | $13.39B | $14.80B | $16.72B | $18.26B |
| Paid-In Capital | $73.3M | $302.5M | $569.4M | $863.1M |
| Retained Earnings | $16.47B | $17.63B | $19.26B | $20.55B |
| AOCI | $-164.9M | $-153.7M | $-136.2M | $-182.0M |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B |
| Total L&E | $24.55B | $26.84B | $28.05B | $29.44B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $2.96B | $1.16B | $1.63B | $1.29B |
| Non-Cash Adjustments | $-1.51B | $1.16B | $1.34B | $1.94B |
| Working Capital Changes | $-71.0M | $-777.4M | $-97.4M | $-1.03B |
| Cash from Operations | $1.38B | $1.55B | $2.88B | $2.20B |
| Capital Expenditures | $240.3M | $277.0M | $153.7M | $153.8M |
| Cash from Investing | $1.58B | $-4.10B | $-799.2M | $-1.37B |
| Debt Issuances | $0 | $997.2M | $0 | $1.73B |
| Debt Repayments | — | — | — | $1.75B |
| Share Buybacks | $750.0M | $0 | $0 | — |
| Cash from Financing | $-1.75B | $149.3M | $-683.5M | $-301.9M |
| FX Effect | $-55.7M | $35.1M | $-67.7M | $101.9M |
| Net Change in Cash | $1.21B | $-2.40B | $1.39B | $531.6M |
| Beginning Cash | $2.26B | $3.42B | $1.05B | $2.38B |
| Ending Cash | $3.42B | $1.05B | $2.38B | $3.01B |
Frequently Asked Questions
How does BIOGEN INC. make money?
Revenue is driven by core therapeutic areas including Alzheimer's disease (dominated by the blockbuster Aduhelm), amyotrophic lateral sclerosis (ALS) via Ryadels, rare neurodegenerative disorders such as spinocerebellar ataxias, and oncology portfolios acquired through strategic mergers.
What are the main risks for BIIB?
Significant reliance on a few blockbuster drugs exposes the company to patent cliffs and pricing pressures, regulatory hurdles in launching new therapies remain high with potential for clinical trial failures, intense competition from large pharmaceutical firms eroding market share, and ongoing healthcare policy changes affecting drug pricing and reimbursement rates.
What is BIIB's competitive advantage?
Biogen possesses deep scientific expertise in neuroscience with a robust pipeline of novel mechanisms of action, an extensive global commercial infrastructure for complex disease management, and a strong brand reputation among neurologists and patients worldwide.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.